What is it about?
The Ca2+-activated K+ channel KCa3.1 is important in cancer cell proliferation, migration and invasion. Therefore, KCa3.1 is a potential therapeutica target for cancer treatment. Histone deacetylase inhibitors are clinically used for cancer treatment. In this study, histone deacetylase inhibition caused decrease in KCa3.1expression and activity in breast cancer cells.
Featured Image
Why is it important?
Our findings demonstrated that the selective inhibition of HDAC2 and/or HDAC3 is a novel therapeutic strategy for drug development focused on KCa3.1 K+ channel-expressing cancer cells such as aggressive breast and prostate cancers.
Perspectives
Epigenetic regulation of KCa3.1 K+ channel may be also involved in the pathogenesis of neurodegenerative, immunological, metabolic, inflammatory, atopic, and cardiovascular disorders. Selective HDAC inhibition of HDAC2 and/or HDAC3 may become therapeutic targets for these diseases.
Dr. Susumu Ohya
Nagoya City University
Read the Original
This page is a summary of: Downregulation of the Ca
2+
‐activated K
+
channel
K
C
a
3.1 by histone deacetylase inhibition in human breast cancer cells, Pharmacology Research & Perspectives, March 2016, Wiley,
DOI: 10.1002/prp2.228.
You can read the full text:
Contributors
The following have contributed to this page
